Danaher Corporation (NYSE:DHR) Stock Holdings Reduced by Fairfield Financial Advisors LTD

Key Points

• Fairfield Financial Advisors LTD reduced its holdings in Danaher Corporation by 46.2%, owning 1,721 shares valued at $353,000.
• Several institutional investors modified their positions, with 79.05% of Danaher stock currently owned by such entities.
• Research analysts have set varying target prices for Danaher shares, with a consensus average target price of $247.61 and a consensus rating of "Moderate Buy."

Fairfield Financial Advisors LTD lessened its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 46.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,721 shares of the conglomerate's stock after selling 1,475 shares during the quarter. Fairfield Financial Advisors LTD's holdings in Danaher were worth $353,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Bank Pictet & Cie Europe AG lifted its holdings in shares of Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after purchasing an additional 35,730 shares during the last quarter. OneAscent Financial Services LLC bought a new stake in shares of Danaher in the 4th quarter worth approximately $251,000. World Investment Advisors lifted its holdings in shares of Danaher by 7.8% in the 4th quarter. World Investment Advisors now owns 13,956 shares of the conglomerate's stock worth $3,204,000 after purchasing an additional 1,008 shares during the last quarter. Arete Wealth Advisors LLC lifted its holdings in shares of Danaher by 23.9% in the 4th quarter. Arete Wealth Advisors LLC now owns 4,681 shares of the conglomerate's stock worth $1,074,000 after purchasing an additional 903 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Danaher in the 4th quarter worth approximately $5,193,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 11.20% of the company's stock.

Danaher Trading Up 1.1%

Shares of Danaher stock traded up $2.25 on Tuesday, reaching $199.71. 756,758 shares of the company were exchanged, compared to its average volume of 4,283,080. The stock has a fifty day moving average price of $197.75 and a 200-day moving average price of $201.87. The firm has a market capitalization of $143.00 billion, a price-to-earnings ratio of 42.43, a price-to-earnings-growth ratio of 2.74 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.72 earnings per share. On average, analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on DHR shares. JPMorgan Chase & Co. cut their price target on Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a report on Friday, July 11th. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Guggenheim reaffirmed a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Bank of America cut their target price on Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.